Is A245620 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A245620 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A245620's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A245620's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A245620?
Key metric: As A245620 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for A245620. This is calculated by dividing A245620's market cap by their current
revenue.
What is A245620's PS Ratio?
PS Ratio
0.8x
Sales
₩73.97b
Market Cap
₩57.44b
A245620 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: A245620 is good value based on its Price-To-Sales Ratio (0.8x) compared to the KR Life Sciences industry average (3.9x).
Price to Sales Ratio vs Fair Ratio
What is A245620's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
A245620 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
0.8x
Fair PS Ratio
n/a
Price-To-Sales vs Fair Ratio: Insufficient data to calculate A245620's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.